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To date our experience with nebulised aztreonam lysine
(AZLI) has been in patients with cystic fibrosis (CF) who
have exhausted all other therapeutic options. These patients
have advanced lung disease and required frequent courses of
intravenous antibiotics. Unfortunately in patients with CF
non-immediate hypersensitivity reactions to beta-lactam antibi-
otics are common. It has been reported that up to 20% of
patients have multiple beta-lactam reactions [1]. At the Region-
al Adult CF Unit in Leeds around 10% of patients have had a
previous hypersensitivity reaction to aztreonam.
We report the use of AZLI in four adult patients with CF and a
history of non-immediate reactions to intravenous aztreonam. All
patients had advanced lung disease with predicted FEV1 ranging
from 17% to 34%. In each case alternative nebulised medication
was either not tolerated or ineffective. Patients 1 and 2 had
developed maculopapular rashes to intravenous aztreonam.
Subsequently Patient 1 failed a desensitisation procedure with
identical symptoms. Patient 3 reported severe arthralgia after
5 days of intravenous treatment. These symptoms recurred on
subsequent re-exposure. Patient 4 developed a fixed drug
eruption to intravenous aztreonam on three occasions.
All patients underwent skin prick testing to ensure no imme-
diate reactivity. Following this a full test dose of AZLI was
given under supervision on a general medical ward. All patients
were skin prick test negative and all test doses were uneventful
with no significant fall in FEV1. Following successful trials all⁎ Corresponding author. Tel.: +44 1132067170; fax: +44 1132065947.
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No adverse events were reported during this period.
AZLI is an aerosolized formulation of aztreonam and lysine
that has been demonstrated to be well tolerated and leads to re-
duction in Pseudomonas Aeruginosa density and improvements
in FEV1 [2]. Structurally there are no differences between the
aztreonam molecule in the nebulised form compared to the in-
travenous preparation although the intravenous preparation
contains arginine rather than lysine. These patients were truly
hypersensitive to aztreonam with three out of four reacting
again on re-exposure in the recent past. The most likely expla-
nation for our observations is that the inhaled route is less im-
munogenic than the intravenous route and a threshold is not
reached in the peripheral circulation to trigger the hypersensi-
tivity reaction. We feel that in patients with mild non-
immediate reactions it is entirely reasonable to have a trial of
treatment. In patients who have had anaphylaxis or a severe
non-immediate reaction then this approach should be avoided.
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